Breaking News Instant updates and real-time market news.

EGLT

Egalet

$1.15

-0.04 (-3.36%)

, CVS

CVS Health

$71.38

0.37 (0.52%)

08:48
12/07/17
12/07
08:48
12/07/17
08:48

CVS removes Egalet's Sprix Nasal Spray from 2018 formulary

Egalet (EGLT) disclosed last night that it has been notified verbally by CVS Caremark (CVS), a pharmacy benefits manager, that Sprix Nasal Spray will no longer be on its formulary for a portion of its commercial covered lives beginning January 1, 2018. Egalet estimates that approximately 20% of Sprix prescriptions could be impacted by Caremark's planned action. In response to this change in coverage, the company intends to continue to work with several other payers to ensure patient access to Sprix. Egalet "believes that its market access strategy will help to enable it to mitigate the impact of this change and help to enable further growth of Sprix, particularly given the Company's relatively nominal share of the market for nonsteroidal anti-inflammatory drugs, or NSAIDs." Egalet shares are down 12c to $1.03 in premarket trading.

EGLT

Egalet

$1.15

-0.04 (-3.36%)

CVS

CVS Health

$71.38

0.37 (0.52%)

  • 12

    Dec

EGLT Egalet
$1.15

-0.04 (-3.36%)

11/09/17
GABE
11/09/17
DOWNGRADE
GABE
Hold
Egalet downgraded to Hold from Buy at Gabelli
Gabelli analyst Kevin Kedra downgraded Egalet to Hold citing challenges for Arymo, potential generic competition for Sprix, and lack of near-term catalysts.
09/12/17
CANT
09/12/17
NO CHANGE
Target $7
CANT
Overweight
Investors should consider owning Egalet, says Cantor
Cantor Fitzgerald analyst Brandon Folkes saying the company's five posters at Pain Week last week reinforced the sales potential of, and need for, abuse deterent products such as Arymo ER. With three approved products and a cash runway through 2020, investors should consider owning Egalet shares, Folkes tells investors in a research note. He reiterates an Overweight rating on the shares with a $7 price target.
08/14/17
CANT
08/14/17
INITIATION
CANT
Overweight
Egalet coverage assumed with an Overweight at Cantor
Cantor analyst Brandon Folkes, assumed coverage of Egalet with a $7 price target and an Overweight rating. He says that the company is poised "to benefit from the need to reduce opioid abuse" while lowering patients' pain. The analyst says that a "strong launch" of the company's Arymo ER drug could spur many more investors to buy its shares.
06/09/17
JMPS
06/09/17
NO CHANGE
JMPS
Egalet may benefit from increased scrutiny of opioids, says JMP Securities
After the FDA requested that Endo (ENDP) remove its Opana ER opioid from the market due to increased risk of abuse using injections, JMP Securities analyst Jason Butler says that Egalet's (EGLT) abuse deterrent opioid alternatives could be boosted by the FDA's increased scrutiny of opioids. The analyst reiterates a $15 price target and Outperform rating on the stock.
CVS CVS Health
$71.38

0.37 (0.52%)

12/06/17
ARGS
12/06/17
DOWNGRADE
ARGS
Hold
Aetna downgraded to Hold from Buy at Argus
Argus analyst David Toung downgraded Aetna (AET) to Hold from Buy following the CVS Health (CVS) merger announcement, saying a more neutral view is now appropriate after a run-up in the stock price which outperformed over the past 5 years. Toung also notes the company is faced with potential risks around regulatory changes in the Medicare Advantage and Medicaid markets as well as possible margin pressure from higher post-merger utilization amid a moderate cost trend medical environment.
12/06/17
BERN
12/06/17
UPGRADE
Target $65
BERN
Market Perform
Express Scripts upgraded to Market Perform from Underperform at Bernstein
Bernstein upgraded Express Scripts to Market Perform from Underperform, with a $65 price target, based upon improved upside risks from potential policy and competitor actions and valuation. Give recent developments, the analyst sees certain upside opportunities to Express Scripts, specifically tax reform, a potential CVS Health (CVS)/Aetna (AET) merger, and a potential entry by Amazon (AMZN) into pharmacy.
12/05/17
BMOC
12/05/17
NO CHANGE
Target $200
BMOC
Market Perform
Aetna-CVS deal is a high risk-reward strategy, says BMO Capital
BMO Capital analyst Matt Borsch is positive on the Aetna (AET) - CVS Health (CVS) merger, saying it accelerates the transformation of healthcare offerings through "the shift to value-based reimbursement, formation of provider 'accountable care organizations', payer-side aggregation of provider assets, and proliferation of lower-cost sites of care" among others. Borsch says that while United Health (UNH) has led this path with Optum, CVS-Aetna partnership may challenge its model. The analyst keeps his Market Perform rating and $200 price target on Aetna, warning that a failed implementation, given the high debt loads and an uncharted path to convert storefronts to healthcare centers, might be "historic".
12/05/17
OPCO
12/05/17
NO CHANGE
OPCO
Perform
Oppenheimer expected higher premium for Aetna shareholders
Oppenheimer analyst Michael Wiederhorn believes CVS Health (CVS) acquisition of Aetna (AET) creates a powerful healthcare competitor. However, he thinks the transaction is more beneficial to CVS given the competitive pressures and need to take action, and he would have expected a higher premium for Aetna shareholders. Wiederhorn reiterates a Perform rating on Aetna's shares.

TODAY'S FREE FLY STORIES

OIH

Oil Services Holders Trust

$18.87

0.37 (2.00%)

14:50
11/21/18
11/21
14:50
11/21/18
14:50
Options
Active trading in VanEck Vectors Oil Services 20-strike calls »

Active trading in VanEck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,529.99

34.39 (2.30%)

14:50
11/21/18
11/21
14:50
11/21/18
14:50
Periodicals
NYC officials say half of Queens Amazon jobs won't be in tech, WSJ says »

New York City officials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

SQM

SQM

$43.70

1.825 (4.36%)

14:49
11/21/18
11/21
14:49
11/21/18
14:49
Options
SQM options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
11/21/18
11/21
14:45
11/21/18
14:45
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

CBFV

CB Financial Services

$25.79

(0.00%)

14:42
11/21/18
11/21
14:42
11/21/18
14:42
Hot Stocks
CB Financial Services increases dividend by 4.5% to 23c per share »

CB Financial Services,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$32.94

4.87 (17.35%)

14:28
11/21/18
11/21
14:28
11/21/18
14:28
Hot Stocks
CD&R Group to buy additional shares in Beacon Roofing »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NTN

NTN Buzztime

$2.70

-0.1 (-3.57%)

14:26
11/21/18
11/21
14:26
11/21/18
14:26
Hot Stocks
Northstar reports 10.33% stake in NTN Buzztime »

On November 21, Northstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:23
11/21/18
11/21
14:23
11/21/18
14:23
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a podcast »

The Commodity Futures…

RHHBY

Roche

$0.00

(0.00%)

, ABBV

AbbVie

$85.75

-2.35 (-2.67%)

14:18
11/21/18
11/21
14:18
11/21/18
14:18
Hot Stocks
Roche announces FDA grants accelerated approval for Venclexta combo »

Roche (RHHBY) announced…

RHHBY

Roche

$0.00

(0.00%)

ABBV

AbbVie

$85.75

-2.35 (-2.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/21/18
11/21
14:17
11/21/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

, RHHBY

Roche

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Hot Stocks
AbbVie says FDA grants accelerated approval to Venclexta-azacitidine combo »

AbbVie (ABBV) announced…

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$54.99

1.4 (2.61%)

14:15
11/21/18
11/21
14:15
11/21/18
14:15
Periodicals
Martin Sorrell to poach senior executive from WPP, Sky News reports »

Martin Sorrell is to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

TGT

Target

$69.10

0.05 (0.07%)

14:10
11/21/18
11/21
14:10
11/21/18
14:10
Options
Target calls lead puts 3:1 after a big drop in shares »

Target calls lead puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HWBK

Hawthorn Bancshares

$22.71

(0.00%)

14:08
11/21/18
11/21
14:08
11/21/18
14:08
Hot Stocks
Ategra stake in Hawthorn Bancshares falls to 4.97% »

As of November 20, Ategra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAM

I-AM Capital

$10.00

(0.00%)

14:04
11/21/18
11/21
14:04
11/21/18
14:04
Hot Stocks
I-AM Capital announces closing of transaction with SMAAASH Entertainment »

Smaaash Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBD

Banco Bradesco

$9.60

0.23 (2.45%)

14:00
11/21/18
11/21
14:00
11/21/18
14:00
Options
Longer-term put buyer in Banco Bradesco »

Longer-term put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

, SPX

S&P 500

$0.00

(0.00%)

13:56
11/21/18
11/21
13:56
11/21/18
13:56
Periodicals
Hedge funds get battered in October and are down for year, CNBC says »

According to a CNBC…

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$5.54

0.07 (1.28%)

13:50
11/21/18
11/21
13:50
11/21/18
13:50
Options
Aggressive call buy in Vipshop »

Aggressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

13:50
11/21/18
11/21
13:50
11/21/18
13:50
General news
Treasury Action: yields remain only marginally firmer »

Treasury Action: yields…

PFE

Pfizer

$43.23

-0.3 (-0.69%)

13:41
11/21/18
11/21
13:41
11/21/18
13:41
Hot Stocks
Pfizer says FDA approves DAURISMO for adults with newly-diagnosed AML »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

  • 10

    Dec

EFA

iShares MSCI EAFE Index Fund

$62.35

1.05 (1.71%)

13:40
11/21/18
11/21
13:40
11/21/18
13:40
Options
Call buying in iShares Emerging Markets Fund and iShares MSCI EAFA Fund »

Call buying in iShares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

13:30
11/21/18
11/21
13:30
11/21/18
13:30
Options
Vix calls lead puts 4:1 as the index drops 9% »

Vix calls lead puts 4:1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$6.95

0.18 (2.66%)

13:25
11/21/18
11/21
13:25
11/21/18
13:25
Options
Akorn call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

OMED

OncoMed

$1.37

(0.00%)

13:22
11/21/18
11/21
13:22
11/21/18
13:22
Hot Stocks
OncoMed awarded European patent for method for making heteromultimeric molecules 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.